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ABSTRACT Histone deacetylase inhibitors (HDACi) modulate the transcriptional activity
of all cells, including innate and adaptive immune cells. Therefore, we aimed to evaluate
immunological effects of treatment with the HDACi panobinostat in HIV-infected pa-
tients during a clinical phase IIa latency reversal trial. Using ﬂow cytometry, we investi-
gated changes in T cell activation (CD69, CD38, HLA-DR) and the expression of CD39
and CTLA4 on regulatory T cells (Tregs). Whole-blood stimulations were performed and
cytokine responses measured using Luminex. Gene expression in puriﬁed peripheral
blood mononuclear cells (PBMCs) was evaluated using an Affymetrix HTA 2.0 gene chip.
We found that proportions of CD4 and CD8 T cells expressing CD69 increased 24 h
after initial panobinostat administration (P  0.01), followed by an increase in the pro-
portions of CD38 HLA-DR-coexpressing CD4 T cells on day 4 (P  0.02). Concur-
rently, proportions of Tregs increased by 40% (P  0.003). Treg CTLA4 median ﬂuores-
cent intensity (MFI) increased by 25% (P  0.007), and CD39 MFI on CD39 Treg
increased by 12% (P  0.02). Lipopolysaccharide (LPS)-induced inﬂammatory responses
(interleukin-1 [IL-1], IL-6, IL-12p40, and tumor necrosis factor alpha [TNF-]) in whole
blood were signiﬁcantly downregulated 4 days after initial dosing. Lastly, panobinostat
induced signiﬁcant changes in the overall gene expression pattern (fold change, 1.5;
false-discovery-rate [FDR]-corrected P, 0.05). Importantly, measures of immune function
returned to baseline after panobinostat treatment and follow-up revealed no sustained
effect on overall gene expression.
IMPORTANCE The effect of treatment with histone deacetylase inhibitors on the im-
mune system in HIV-infected individuals is not clear. Analysis of results from a clini-
cal trial in which 15 HIV-infected individuals received 12 doses of panobinostat iden-
tiﬁed a signiﬁcant impact on both T cell activation status and regulatory T cell
suppressive marker expression and a reduced level of monocytic responsiveness to
inﬂammatory stimuli. These changes were substantiated by global gene expression
analysis. Collectively, the results suggest that panobinostat has multiple effects on
innate and adaptive immune responses. Importantly, all the effects were transient,
and further panobinostat treatment did not cause persistent long-term changes in
gene expression patterns in HIV-infected individuals.
KEYWORDS T-cell immunity, clinical trials, gene expression, histone deacetylase
inhibitors, human immunodeﬁciency virus, inﬂammation
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Histone deacetylase inhibitors (HDACi) are known for their ability to modulate theepigenetic regulation of multiple genes, which in the ﬁeld of HIV eradication has
been exploited to reactivate latent HIV (1). We recently conducted a clinical trial in
HIV-1-infected patients on combination antiretroviral therapy (cART) to investigate the
ability of the HDACi panobinostat to disrupt HIV-1 latency (2). Here, a successful
reactivation of viral transcription by the use of panobinostat has established that this
HDACi is a potential future latency reversal agent (LRA) suitable for use in a curative
strategy. However, a comprehensive analysis of the impact of panobinostat on the
immune system is a necessity for fully evaluating its potential in future clinical trials.
HDACi were originally developed for the treatment of hematologic malignancies by
virtue of their capacity to cause growth arrest, differentiation, and apoptosis of tumor
cells (3). The same is true for panobinostat, being a highly potent oral pan-HDACi
recently approved for the treatment of multiple myeloma (4). HDACi reversibly inhibit
the activity of histone deacetylases (HDACs) and thereby modify gene expression and
inﬂammatory responses (5, 6). While the immunoregulatory properties of HDACi have
considerable therapeutic potential to target pathological inﬂammation (7), the toxici-
ties associated with the dosages used for cancer treatment have impeded the devel-
opment of HDACi as immunomodulatory drugs in other diseases. However, it should be
noted that the immunomodulatory effects of HDACi are elicited at much lower con-
centrations than those required for direct antitumor effects, expanding the range of
their beneﬁcial uses (8–11).
HDACi affect pathological tissue differently from normal tissue; e.g., malignant cells
are more sensitive to HDAC inhibition than nonmalignant cells, and antineoplasm
effects dominate over immunomodulatory effects when both cell types are present in
vivo (12). The latter observation might explain why contradictory results arise from in
vitro models, animal models, and human studies. In fact, the overall effect of HDACi
treatment on host immune pathways appears to vary with both the applied model
system and the indication for which HDACi is administered. Therefore, interpretation of
preclinical data requires careful consideration and necessitates conﬁrmation of ﬁndings
in clinical trials. However, the clear majority of clinical HDACi trials have been con-
ducted in the oncology ﬁeld, and those studies have offered little insight into immu-
nological effects of HDACi treatment in patients without malignancy. Hence, a deeper
understanding of the immunomodulatory effects of HDACi in nononcology patients is
much needed to guide the potential development of HDACi for the treatment of other
disease indications such as their use in anti-inﬂammatory and curative HIV strategies.
Our recent clinical trial provided a unique opportunity to comprehensively evaluate
the diverse immunomodulatory effects of panobinostat in vivo in the context of chronic
HIV infection. We previously described the immunological impact of panobinostat on
interferon-stimulated genes, HIV-speciﬁc cytokine production, and biomarkers of car-
diovascular risk (13, 14). Thus, here we expand this immune cell proﬁling by reporting
on T lymphocyte characterizations, innate immune responses, and extensive gene
expression proﬁling in peripheral blood mononuclear cells (PBMCs). Providing this
additional view into the immune system thereby offers invaluable information about
the impact of panobinostats on HIV-1-infected patients to guide its future use as a
component of HIV eradication efforts.
RESULTS
T cell activation. To determine the impact of repeated panobinostat dosing on
overall T cell activation, we evaluated the expression of the early T cell activation
marker CD69 throughout the study (Fig. 1A and B). At 24 h following panobinostat
administration, we recorded an increase in the proportions of both CD4 T cells (P 
0.002) and CD8 T cells (P  0.0005) expressing CD69 (Fig. 1C). CD69 expression was
also elevated on day 28 (at the start of third treatment cycle) but returned to baseline
levels for both CD4 and CD8 T cells 4 weeks after completion of panobinostat
treatment (on-panobinostat). A similar pattern of increase, albeit occurring less
promptly and in a less pronounced manner, was observed for CD38 HLA-DR doubly
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positive T cells. We observed no change at 24 h after initiation of panobinostat.
However, the proportion of T cells positive for CD38 and HLA-DR was modestly
increased for CD4 (but not CD8) T cells on day 4 post-panobinostat initiation (P 
0.02) (Fig. 1D). Of note, no subset speciﬁc evaluation was done.
FIG 1 Impact of panobinostat on T cell activation and its possible relation to measurement of viral replication. (A) Study design
depicting 20 mg panobinostat dosing three times per week every other week for a total of 8 weeks. (B) Time points of analysis
outlined: baseline; 24 h after the ﬁrst dosing; day 4 (8 h postdosing); day 28 (8 h postdosing); at follow-up on day 84, 4 weeks
after last dosing. (C) Percentages of CD4 and CD8 T lymphocytes expressing the early activation marker CD69 during the
study. (D) Percentages of CD4 and CD8 T lymphocytes expressing both late activation marker HLA-DR and activation marker
CD38 during the study. (E) Correlation between CD8 CD69 fold change (visit8/baseline) and AUC for plasma panobinostat
concentrations from baseline through v8. (F) Correlation between levels of CA-US HIV-1 RNA and CD38 HLA-DR T cells.
Changes in T cell expression patterns compared to baseline were evaluated by a paired t test. Correlations were evaluated
using Pearson’s correlation. Means and standard errors of the means (SEM) of results are depicted. *, P  0.05; **, P  0.01;
***, P  0.001.
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To assess the impact of plasma panobinostat concentrations (2) and their relation to
T cell activation, we correlated levels of fold change in activation (baseline to day 4 and
day 28) to area under the curve (AUC) values for plasma panobinostat in the same time
frame, as a measure of total drug exposure impact. We observed a signiﬁcant correla-
tion of levels of fold change in CD69 expression between CD4 (not shown) and CD8
T cells (Fig. 1E) on day 28, whereas no signiﬁcant correlation was observed for CD38
HLA-DR T cells.
To investigate a possible relationship between T cell activation and viral transcrip-
tion, we next correlated expression of activation markers to the previous investigated
levels of cell-associated unspliced HIV-1 RNA (CA-US HIV-1 RNA) found in CD4 T cells
as a biomarker of viral transcriptional levels (previously published [2]). We found no
signiﬁcant correlations between CD4 T cell activation and the level of transcription
(data not shown). However, examining CD8 T cell activation, we observed a signiﬁcant
inverse correlation (P  0.0001) between the levels of transcription and of CD38
HLA-DR T cells at baseline (Fig. 1F).
The impact of panobinostat on Tregs.We deﬁned the regulatory T cell population
as CD3 CD4 CD45RA and Foxp3high (15) (Fig. 2A). The proportion of Tregs increased
following panobinostat dosing, with a 40% increase on day 4 (P  0.003). Levels of
Tregs were also elevated on day 28 of panobinostat treatment (P 0.004) but returned
to baseline at follow-up (Fig. 2B). Furthermore, the median ﬂuorescent intensities (MFI)
of suppressive marker CTLA-4 (on total Tregs) and CD39 (on CD39 Tregs) increased
signiﬁcantly in the ﬁrst dosing week by 25% and 12%, respectively (Fig. 2C and D). The
increase in CTLA4 expression shortly following panobinostat initiation was not main-
tained, as levels were comparable to baseline at day 28 on-panobinostat (Fig. 2C), in
contrast to the level of Treg CD39 expression, which remained signiﬁcantly elevated on
day 28 on-panobinostat (P  0.006) but returned to baseline at follow-up 4 weeks
post-panobinostat initiation (Fig. 2D).
FIG 2 Panobinostat affects the levels of regulatory T cells and inhibitory receptor expression. (A) Gating
deﬁnition of regulatory T cells (Treg). PE, phycoerythrin. (B) Relative changes in levels of Treg (CD4
CD45RAneg FoxP3high) during the course of panobinostat therapy. (C) Relative changes in intracellular
expression of the suppressive marker CTLA4 in Treg. (D) Relative changes in expression of the suppressive
marker CD39 on Treg. Changes in levels of expression (median ﬂuorescence intensity [MFI]) compared to
baseline were evaluated by a paired t test. Means and SEM are depicted. *, P  0.05; **, P  0.01; ***;P 
0.001.
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Whole-blood responsiveness to LPS stimulation. To determine functional changes
in immune responsiveness, whole-blood stimulations were performed with lipopoly-
saccharide (LPS). The LPS responses, as assessed by levels of interleukin-1 (IL-1), IL-6,
tumor necrosis factor alpha (TNF-), and IL-12p40 secretion, were all signiﬁcantly
downregulated by panobinostat (day 28) (Fig. 3A to D). In contrast, secretion of IL-8,
IL-18, gamma interferon (IFN-), and IFN--induced protein 10 (IP-10) in response to LPS
stimulation was not affected by panobinostat treatment (Fig. 3E to H).
Analysis of control samples, i.e., whole blood not exposed to LPS but left untouched
overnight, revealed an interesting pattern. Treatment with panobinostat primed a Th1
response with increased secretion of IL-18, IFN-, and IP-10 compared to baseline (P 
0.05; Fig. 4A to C). However, this priming did not represent a broad inﬂammatory
activation response pattern, as IL-6 and IL-8 levels remained unchanged (Fig. 4D and E).
FIG 3 LPS induced cytokine production in whole blood inhibited by panobinostat treatment. LPS induced release of
cytokines/chemokines from 24-h whole-blood stimulations at day 28 (On Treatment). Samples were available from 7 patients.
The Wilcoxon matched-pair signed-rank test was used. Medians are depicted. *, P  0.05; **, P  0.01.
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TNF-, IL-1, and IL-12p40 were undetectable under all unstimulated conditions (data
not shown).
Change in epigenetic regulation of gene expression. We identiﬁed genes that
were differentially expressed during treatment with panobinostat by considering three
pairwise comparisons among three visits: baseline (visit 2 [V2]), day 4 on-panobinostat
(V4), and follow-up 4 weeks post-panobinostat initiation (V12). We identiﬁed 383 gene
transcripts that were differentially expressed between baseline and day 4, 244 tran-
scripts that were differentially expressed between day 4 and post-panobinostat initia-
tion follow-up, and only 16 transcripts that were differentially expressed between
baseline and follow-up 4 weeks post-panobinostat initiation (Fig. 5A). Of note, no
changes in gene expression were detected at an additional long-term follow-up visit
24 weeks post-panobinostat dosing (V13) compared to baseline (data not shown). Tight
clustering of affected genes at day 4 on panobinostat is visualized in the heat map in
Fig. 5B and in the principal-component analysis (PCA) depicted in Fig. 5C. Overall, these
data show that panobinostat induced signiﬁcant perturbations in gene expression
patterns that were fully reversible after panobinostat treatment discontinuation. Nota-
bly, when we performed a functional annotation of genes differentially expressed
FIG 4 Spontaneous release of Th1 derived cytokines is inﬂuenced by panobinostat treatment. (A-E)
cytokine/chemokine production from 24 h whole blood without LPS stimulation. TNF-, IL-1, and IFN-
were all undetectable (data not shown). On Treatment, day 28. Samples were available from 7 patients.
The Wilcoxon matched-pair signed-rank test was used. Medians are depicted. *, P  0.05.
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FIG 5 Panobinostat induces reversible perturbations in PBMC gene expression patterns. (A) Venn diagram summarizing the number of differentially expressed
genes (DEG) in comparisons between the indicated study visits. V2, baseline; V4, day 4 of panobinostat treatment; V12, follow-up. (B and C) Heat map (B) and
principal-component analysis (C) of 428 transcripts differentially expressed between V2, V4, and V12. Data points from V2, V4, and V12 are indicated in orange,
blue, and green, respectively. (D) R-Circos plot summarizing functional pathways enriched for DEGs. Outer circles reﬂect selected functional pathways and
corresponding DEGs (PRBV, role of pattern recognition receptors; NFATIR, NFAT-dependent immune regulation; LES, leukocyte extravasation signaling; IL17S,
IL-17 signaling; PI3KS, PI3K signaling; TREM1S, TREM1 signaling; IL8S, IL-8 signaling; fMLPS, fMLP signaling; TecKS, tec kinase signaling). Inner circles indicate
levels of gene expression intensity (median gene z scores) of the respective transcripts at the indicated study visits. (E) Plasma IL-1 levels (in picograms per
milliliter). A paired t test was performed, and the means of the results are depicted.
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during panobinostat dosing, we identiﬁed pathways related to a diverse spectrum of
biological functions, including gene clusters involved in the regulation of pattern
recognition pathways (PRBV [role of pattern recognition receptors]), IL-8- and IL-17-
mediated signal transduction mechanisms (IL8S and IL17S), leukocyte extravasation
signaling (LES), and the TREM1- and the phosphatidylinositol 3-kinase (PI3K) signaling
cascades (Fig. 5D). Since caspase-1-mediated pyroptosis has been suggested to be an
important contributor to CD4 T cell depletion (16), it was an interesting ﬁnding that
IL-1 expression was signiﬁcantly decreased on-panobinostat. Investigating plasma
concentrations of IL-1 using a high-sensitivity assay, we observed a tendency toward
less production at day 4 on-panobinostat (P  0.06) (Fig. 5E).
Correlations between gene expression changes and CA-US HIV-1 RNA. To
further explore gene expression changes occurring during panobinostat treatment, we
focused on transcriptional alterations between baseline and day 4 on-panobinostat. For
this purpose, correlations between fold changes (binary logarithms [log2]) in levels of
gene expression in PBMCs and corresponding fold changes in levels of CA-US HIV-1
RNA between baseline and day 4 were analyzed by Spearman’s correlation. A total of
2,828 gene transcripts were identiﬁed, with a nominal P value of 0.05. Transcripts
strongly correlated with corresponding changes in CA-US HIV-1 RNA levels were
functionally involved in cellular interactions mediated by IL-6, IL-8, IL-15, IL-18, and
inducible costimulator/inducible costimulator ligand (iCOS/iCOSL), in antigen presen-
tation and immune recognition pathways, and in beta-catenin and ILK signaling
pathways (Fig. 6).
DISCUSSION
In recent years, HDACi have been utilized in an increasing number of human studies
targeting nonneoplastic diseases, including HIV-1 infection (5). However, comprehen-
sive analyses of the impact of HDACi on the immune system are lacking, impeding
efforts to design a more effective future method of use. In this study, we expanded our
previous knowledge by exploring broad immunological changes induced during pano-
binostat dosing in HIV-1-infected individuals. Treatment with panobinostat resulted in
a signiﬁcant but transient increase in T cell activation, Treg proportions, and Treg
expression of CTLA4 and CD39. Further, we observed lowered functional LPS respon-
siveness, with a countervailing Th1 phenotypic increase. The impact on innate signaling
was rediscovered in the gene expression proﬁling, showing a marked transcriptional
decrease on multiple innate signaling pathways. Importantly, all measures of immune
function had returned to baseline levels 4 weeks after completion of panobinostat
treatment, and follow-up examinations revealed no sustained effect on overall gene
expression.
Several previous reports indicated that HDACi stimulation caused moderate T cell
activation in vitro and in vivo (17–19), whereas other studies showed that HDACi inhibit
the cytotoxic and proliferative capacity of activated or antigen-stimulated T cells (20,
21). Of note, previous data from our panobinostat clinical trial indicated no decrease in
HIV-speciﬁc cytokine production as evaluated by intracellular cytokine staining (ICS)
and enzyme-linked immunosorbent spot (ELISPOT) assays but instead a signiﬁcant
increase in the magnitude and breadth of the responsiveness of CD8 T cells in the
ELISPOT assay (13). In this study, panobinostat treatment resulted in a signiﬁcant
upregulation of surface activation markers on T lymphocytes, in line with results seen
with other HDACi. CD69 is a transmembrane C-type lectin and one of the earliest
proteins expressed after lymphocyte activation, with a key role in responses to inﬂam-
mation and modulation of adaptive immune responses (22, 23). CD69 is tightly regu-
lated at the transcriptional level, with nucleosome promoter positioning and histone H3
acetylation as important transcriptional determinants (24). Thus, the rapid induction of
CD69 after dosing could be ascribed to a direct pharmacological effect of promoting
histone acetylation or acetylation of proteins other than histones. Likewise, we simul-
taneously observed minor upregulations of CD38 and HLA-DR on CD4 T cells. This
increase could suggest a bona ﬁde phenotypic activation of the lymphocyte compart-
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ment. In our observations, we also found that total panobinostat exposure over a
longer time period (AUC, baseline through v8) correlated with the induction of CD69
expression on both CD4 and CD8 T cells. We were unable to decipher any direct
impact of panobinostat or whether it is a secondary effect that subsequent initiates
higher-level activation, for example, mediated by the higher level of HIV transcription
as observed in this study.
The ability to activate the T cell compartment is an interesting observation in the
context of inducing transcription of latent HIV-1. One of the key transcriptional regu-
lators during T cell activation is the nuclear translocation of NF-B, which is also an
important determinant of efﬁcient transcriptional initiation of the HIV-1 long terminal
repeat (LTR) (25–27). We did not assess HDACi-induced NF-B activation in this study;
however, such an assessment would make an interesting observation in future clinical
FIG 6 Gene expression changes associated with induction of cell-associated US HIV-1 RNA transcription
during treatment with panobinostat. (A) Linear regression of fold changes between day 4 and baseline
(V4 to V2) expressed in levels of gene expression intensity of host genes and corresponding changes in
CA-US HIV-1 RNA. The heat map reﬂects all host transcripts correlated with CA-US HIV-1 RNA on a
nominal P level of 0.05. Patients were ranked according to the intensity of CA-US HIV-1 RNA induction.
(B) R Circos plot indicating gene sets enriched for host transcripts associated with CA-US HIV-1 RNA, as
determined by linear regression calculated as described for panel A. Outer circles reﬂect the following
gene set pathways: Wnts, Wnt signaling; NFATIR, NFAT-dependent immune regulation; mTORS, mTOR
signaling; JAKS, JAK/STAT signaling; ILKS, ILK signaling; iCOS, iCOS/iCOL signaling; CDN, crosstalk
between NK cells and dendritic cells; BRS, BCR signaling; APP, antigen presentation pathway; IL17S, IL-17
signaling; IL6S, interleukin-6 signaling; IAHIV1, induction of apoptosis by HIV; IL88S, interleukin-8
signaling; EIF2S, EIF2 signaling. Inner circles indicate fold changes (V4 to V2) for each individual transcript,
and rho values (Spearman’s correlation coefﬁcient) reﬂect the correlations with the corresponding CA-US
HIV-1 RNA levels.
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studies. The slightly enhanced activation of the CD4 T cell compartment may con-
tribute to the efﬁcacy by which panobinostat induces expression of latent HIV-1
proviruses. Correlating the levels and changes in the levels of CA-US HIV RNA as a
marker of transcription to the levels and changes in the levels of CD4 T cell activation,
we did not, however, ﬁnd any signiﬁcant correlations to support this hypothesis. This
suggests that latency reversal can happen independently of T cell activation. Instead, a
direct cell sorting of CD4 T cells based on activation status with a subsequent analysis
of transcriptional activity could be done in future clinical studies to address this
speciﬁcally. Investigating the CD8 T cells, we did, however, observe a highly statisti-
cally signiﬁcant inverse correlation between the baseline transcriptional activity and the
percentage of CD38 HLA-DR T cells. CD8 cytotoxic T cells have always been known
to represent a sentinel cell type in the control of HIV (28). In an HIV-curative context,
this seems to underline the importance of CD8 T cells in controlling transcriptional
activity and thus could potentially be used as a prestudy biomarker for individuals with
a higher likelihood of being able to control virus.
We noted signiﬁcant (up to 40%) expansion in the regulatory T cell population
during panobinostat treatment. This observation is in line with previous reports de-
scribing vorinostat treatment in HIV-1-infected individuals (29) and in allogeneic he-
matopoietic stem cell transplantation (HSCT) recipients (30). Importantly, another study
has shown that HDAC inhibition increases Foxp3 gene expression, resulting in en-
hanced Treg suppressive function (31). In humans, inhibition of HDAC6 appears im-
portant for Treg induction (32). Both vorinostat and panobinostat have been shown to
inhibit HDAC6 in the lower nanomolar range. In line with this, we observed increased
expression of suppressive markers CD39 and CTLA-4 in the Treg population, and the
latter has been shown to correlate tightly with Treg functional suppressive capacity
(33). From an HIV-1 eradication perspective, the increase in Treg function during HDACi
treatment could be counterproductive, given that Treg depletion has been shown to
support disruption of viral latency (34), and may also contribute to inhibition of antiviral
effector cells. Recently, a CTLA4 PD-1 T cell type that shares phenotypic markers with
Tregs was shown to constitute a part of the HIV reservoir (35). The increase in levels of
CTLA4 expression and Treg percentages that we observed could therefore be seen as
potentially problematic in a context of homeostatic proliferation. The fact that we did
not observe an increase in CD4 total HIV DNA levels in the time frame of these peak
incidences but instead observed a signiﬁcant decrease (2) speaks against this concern.
On the other hand, the clear induction of Treg may more reasonably be interpreted as
a sign of a well-balanced unperturbed immune response counteracting the observed
increased activation mediated by heightened T cell activation and Th1 priming.
HDACi have inhibitory effects on inﬂammatory cytokine production in cells of the
innate immune system, e.g., monocytes, activated macrophages, and dendritic cells (10,
11, 36–39). A remarkable indication of this potential stems from a recent study in which
a reduced dose of vorinostat (100 or 200 mg) added to the standard immunoprophy-
laxis for graft-versus-host disease (GVHD) following hematopoietic stem cell transplan-
tation (HSCT) was associated with suppression of inﬂammatory cytokines, an increase
in Treg, and an incidence of severe acute GVHD that was lower than expected (40). To
characterize the immune responsive capacity during panobinostat treatment, we there-
fore performed whole-blood stimulations on freshly drawn blood before, during, and
after dosing. In contrast to dissection of all cell types and responses, whole-blood
stimulations provide a “true-to-nature” assay that includes all cell types in relevant
concentrations, soluble receptors, and cytokines, essentially representing a complete
peripheral immunological replicate. In the light of the impact of microbial transloca-
tions on chronic activation of the immune system in HIV-infected individuals, we chose
to use stimulation with LPS as a classic indicator to establish whether panobinostat
could attenuate this repeated microbial activation, beneﬁting the ﬁtness of the immune
system. Stimulation with LPS revealed a diminished inﬂammatory response indicated
by decreased secretion of IL-1, L-6, TNF-, and IL12p40. This is consistent with our
previous report showing an anti-inﬂammatory effect of panobinostat treatment as
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evidenced by signiﬁcant decreases in plasma levels of C-reactive protein (CRP) and
sCD40L (14). These decreased inﬂammatory responses, in conjunction with the analyses
of the gene expression data showing a signiﬁcant reduction in levels of genes associ-
ated with pattern recognition receptor responses (such as Toll-like receptor 4 [TLR4]),
suggest a powerful modulatory effect of panobinostat on these innate immune path-
ways. Such modiﬁcations in the inﬂammatory responses following TLR4 stimulation
have also been reported with givinostat (ITF2357) (10) and vorinostat (30). Other
intriguing ﬁndings emerged from the whole-blood stimulations. In PBMCs of unstimu-
lated whole blood, we found a signiﬁcant upregulation of IFN- as well as IP-10 and
IL-18. This is strongly indicative of a primed Th1 response and was corroborated by the
ﬁnding that the IFN- gene was one of the single genes with the greatest fold change
increase in the gene expression analysis. In that context, we previously reported
ELISPOT assay results showing HIV-speciﬁc IFN- increases in both magnitude and
breadth after panobinostat treatment, which further validates the corresponding ﬁnd-
ings. IFN- is important in induction of cellular immune effector functions (i.e., cytotoxic
T cells and/or natural killer [NK] cells, both of which are believed to be key components
in the pursuit of an effective HIV eradication strategy). That we have observed IFN- to
be upregulated by panobinostat in multiple assays does represent a unique feature of
this HDACi.
What is also evident from the data presented here is the profound impact of
panobinostat on multiple innate and adaptive components of the immune system. We
observed that global transcriptional signatures in PBMCs during panobinostat treat-
ment showed highly distinct patterns, with changes in a broad spectrum of immune
pathways, including pattern recognition pathways. While many of these transcriptional
changes likely reﬂect unspeciﬁc effects related to HDACi-induced epigenetic variations
in transcriptional control mechanisms, we also identiﬁed 2,828 transcripts with tran-
scriptional alterations that closely correlated to corresponding changes in CA-US HIV-1
RNA levels. Of note, such transcripts were enriched for genes inﬂuencing cell-to-cell
interaction and intercellular communication and were involved in innate immune
recognition and antigen presentation pathways, iCOS/iCOSL-dependent cell signaling
events, and intercellular communication mediated by IL-6, IL-8, IL-15, and IL-18. To-
gether, these data invite the hypothesis that, in addition to cell-intrinsic direct phar-
macological effects of HDACi on HIV-1 transcription, HDACi may also inﬂuence HIV-1
gene expression by indirect mechanisms that result from altered cellular interaction
pathways and from changes in microenvironmental signals. Precisely how such altered
cell-to-cell interactions may possibly contribute to viral reactivation during HDACi
treatment represents an important area of investigation in future studies. In addition,
the observed decreases in both IL-1 gene expression and protein plasma concentra-
tions could suggest additional beneﬁcial impacts of panobinostat. Given the hypothesis
of pyroptosis mediating CD4 T cell death, an inhibition of caspase-1 activity in CD4
T cells would make the use of this HDACi highly attractive. One HDACi with this ability,
givinostat (ITF2357), has already been reported to inhibit caspase-1 activity in stimu-
lated PBMCs (41).
Despite addressing important aspects relevant for future HDACi utility, certain
limitations should be noted. Primarily, due to the lack of a control group, we are unable
to account for naturally occurring longitudinal variations in our measurements. How-
ever, the timing and rapidity of changes in both innate and adaptive compartments
closely coinciding with the panobinostat administration are strongly suggestive of a
causal relationship. In addition, as the gene expression analysis was made using total
PBMCs, no immune compartment-speciﬁc impact can be inferred.
In conclusion, we found that treatment of HIV-1-infected individuals with the HDACi
panobinostat signiﬁcantly but transiently inﬂuenced T cell activation, increased pro-
portions of Treg, and decreased functional mitogen responsiveness. Panobinostat also
affected gene expression and impacted immune pathways. Alterations in immune
functions normalized within 4 weeks after stopping panobinostat treatment and a
long-term follow-up revealed no sustained effect on overall gene expression. Collec-
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tively, these results suggest that panobinostat causes neither persistent transcriptional
changes nor persistent immunomodulatory changes in HIV patients.
MATERIALS AND METHODS
Study design. We performed a single-arm, phase 1/2 trial at the Department of Infectious Diseases,
Aarhus University Hospital, Aarhus, Denmark (ClinicalTrials registration no. NCT01680094). Brieﬂy, 15
HIV-infected adults on suppressive cART (50 copies per ml for at least 2 years) with a CD4 count above
500 cells per l were enrolled (2). Study participants received oral panobinostat (20 mg) three times per
week every other week for a total of 8 weeks while maintaining cART coverage (Fig. 1A). Blood sampling
was done at multiple time points before, during, and after panobinostat administration. Samples used for
this study were collected at baseline (day 0 [visit 2]), day 1 (24 h after the ﬁrst dose [visit 3]), day 4 (8 h
after third dose [visit 4]), day 28 (8 h after the seventh dose [visit 8]), and day 84 (4 weeks after the last
dose [visit 12]) (Fig. 1B). Additional detailed information on inclusion and exclusion criteria has previously
been published (2). The study was approved by the Danish Research Ethics Committee system and
conducted in accordance with the principles of the Declaration of Helsinki. Each participant provided
written informed consent before initiation of any study procedures.
T cell activation and Treg. Using ﬂow cytometry, we evaluated both T cell activation status and
suppressive marker expression on Treg throughout the study. For assessment of activation status, we
investigated the activation markers CD69, HLA-DR, and CD38 (for Treg) and the suppressive capacity
markers CD39 and CTLA4.
For analysis of T cell activation status, 4  105 cryopreserved PBMCs were thawed and immediately
stained with a viability dye (near-infrared [near-IR]; Life Technologies) for 30 min on ice. Afterward,
nonspeciﬁc binding was blocked using 10% fetal bovine serum (FBS) and the cells were subsequently
surfaced stained (30 min, 4°C) with antibodies to CD3 (SK7; BioLegend), CD4 (RPA-T4; BD), CD8 (SK1; BD),
CD69 (fn50; BioLegend), CD38 (HB7; BD), and HLA-DR (G46-6; BD). Gates for activation marker positivity
were determined using isotope control antibodies. For the Treg setup, we followed the same procedure,
using 1  106 cryopreserved PBMCs and antibodies to CD3 (SK7; BioLegend), CD4 (OKT4; BioLegend),
CD45RA (HI100; BD), CD25 (M-A251; BD), and CD39 (A1; BioLegend). In addition, cells were ﬁxed,
permeabilized (transcription factor buffer set; BD), and subjected to intracellular staining (45 min, 4°C)
with FoxP3 (236a/E7; BD) and CTLA4 (BNI3; BD). Treg were deﬁned as CD4 CD45RA FoxP3high T cells.
Foxp3intermediate-expressing CD4 T cells were not included in the analyses, as they do not exhibit the
same immunosuppressive properties (15).
Both setups were run on a FACSVerse ﬂow cytometer (BD Biosciences) with the use of CompBeads
(BD Biosciences) for compensation. All antibodies were titrated before use, and all analyses were
performed in FlowJo (ThreeStar, NJ, USA).
Cytokine production in whole-blood stimulations and plasma. Whole-blood stimulations were
performed to reveal any changes in the combined-response potential of cells in the peripheral blood. We
used 250 l of freshly harvested blood (heparin) transferred to two separate microcentrifuge tubes.
Subsequently, the blood volumes in both tubes were diluted four times by adding 750 l RPMI medium;
one of the tubes included a ﬁnal concentration of 100 ng/ml of lipopolysaccharide (LPS; Sigma). Both
tubes were incubated overnight at 37°C in the incubator with the lid open to allow CO2 buffering. The
following day, supernatants were gently harvested and immediately frozen at 80°C. We evaluated the
production of IL-1, IL-6, IL-8, IL-12p40, IP-10, IL-18, TNF-, and IFN- on a Luminex 100 platform, using
multiplex antibodies from Bio-Rad as recommended by the manufacturer. Whole-blood stimulations
were performed for 7 patients at baseline, on-panobinostat (day 28), and at follow-up. Plasma measure-
ments of IL-1 levels were done using a high-sensitivity Ella platform (ProteinSimple; R&D Systems). We
used single cytokine cartridges for IL-1 according to protocol, using plasma (EDTA tubes) from baseline,
on-panobinostat (day 4), and follow-up, and stored them throughout the study at 80°C.
Gene expression microarrays. The effect of panobinostat on gene expression was evaluated using
an Affymetrix Human Transcriptome 2.0 array (42). Brieﬂy, using PAXgene blood RNA tubes (PreAnalytiX),
ﬁve million PBMCs were directly lysed following isolation. Samples were stored at 80°C. RNA isolation,
RNA integrity veriﬁcation, hybridization to the Affymetrix Human Transcriptome 2.0 array (70,523
probes), and realigning were performed (Aros Applied Biotechnology, Aarhus, Denmark). Gene expres-
sion was evaluated at baseline (visit 2), day 4 on-panobinostat (visit 4), and follow-up (visit 12) for all
patients. Gene expression data were normalized using Robust Multi-Array Average (RMA) algorithms (43).
Statistical analysis. We analyzed ﬂow cytometry and whole-blood cytokine data using either a
paired t test or a Wilcoxon matched-pair signed-rank test comparing baseline data to data from speciﬁc
on-panobinostat time points. Correlations were determined using Pearson or Spearman analyses.
Two-tailed P values below 0.05 were considered signiﬁcant. GraphPad Prism (GraphPad Software, Inc.),
version 6, was used for statistical analysis and for graphical presentation of T cell and cytokine data. For
gene expression analysis in microarrays, the LIMMA (44) method was used for pairwise detection of
differentially expressed gene transcripts; gene expression changes with a fold change value of 1.5 and
a false-discovery-rate (FDR)-adjusted P value of 0.05 were considered signiﬁcant. Principal-component
analysis (PCA) of microarray data was performed using the “prcomp” function in R (45), and the WARD
method implemented in R was used for unsupervised hierarchical clustering analysis of gene expression
data as visualized in the presented heat maps. Spearman correlations were used to identify correlations
(P  0.05) between fold changes of gene expression data (log2) and corresponding fold changes of
unspliced HIV-1 RNA data. Functional annotations of microarrays data were determined by Ingenuity
pathway analysis (IPA). Graphical presentation of gene expression data as heat maps and Circos plots was
carried out using R.
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Accession number(s). All data were deposited in a public repository (GEO) and can be accessed via
accession no. GSE109792.
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